The Sky Shop For Hope
Women's Lightweight Zip Hoodie (Embroidered Sky Logo)
Women's Lightweight Zip Hoodie (Embroidered Sky Logo)
Couldn't load pickup availability
Not just a wardrobe essential, this hoodie supports a meaningful mission. 40% of all revenue from the Unity Zip-Up Support Hoodie goes to Sky Foundation, a non-profit that funds pancreatic cancer research, letting every purchase contribute to positive change.
- Lightweight fabric (5.6 oz/yd² or 189.9 g/m²) for year-round comfort
- 50% polyester, 25% airlume combed ring-spun cotton, 25% rayon blend
- Unisex fit (men may want to order a size up for a relaxed fit)
- Side-seamed construction for a tailored look
- Hood and kangaroo pocket for added functionality
Note: Embrace comfort and show support for pancreatic cancer research with every wear.
Size guide
CHEST TO FIT (inches) | CHEST (inches) | LENGTH (inches) | |
XS | 31-34 | 14 ¾ | 24 ⅞ |
S | 34-37 | 16 ¼ | 25 ¾ |
M | 38-41 | 18 ¼ | 26 ⅞ |
L | 42-45 | 20 ¼ | 28 |
XL | 46-49 | 22 ¼ | 29 ⅛ |
2XL | 50-53 | 24 ¼ | 30 ¼ |
CHEST TO FIT (cm) | CHEST (cm) | LENGTH (cm) | |
XS | 78.7-86.4 | 37.5 | 63.2 |
S | 86.4-94 | 41.3 | 65.4 |
M | 96.5-104.1 | 46.4 | 68.3 |
L | 106.7-114.3 | 51.4 | 71.1 |
XL | 116.8-124.5 | 56.5 | 74 |
2XL | 127-134.6 | 61.6 | 76.8 |
Share































Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...